6-K - GDTC - Equibles

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

WASHINGTON,D.C. 20549

FORM6-K

REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDERTHE SECURITIES EXCHANGE ACT OF 1934

For the Financial Period Ended 30 Jun 2024

CommissionFile Number: 001-41677

CytoMedTherapeutics Limited

(Exact name of registrant as specified in its charter)

1Commonwealth Lane

#08-22

Singapore149544

(Addressof Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Yes ☒ No ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes ☐ No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes ☐ No ☒

INFORMATIONCONTAINED IN THIS FORM 6-K REPORT

CytoMed Therapeutics Limited (the “Company”) is hereby furnishing this report on Form 6-K (the “Report”) to provide the Unaudited Interim Condensed Consolidated Financial Statements of the Company for the six months ended June 30, 2024, included as Exhibit 99.1 of this Report, the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2024, included as Exhibit 99.2 of this Report, and a press release dated September 30, 2024 announcing corporate updates and the financial results for the six months ended June 30, 2024 of the Company, included as Exhibit 99.3 of this Report.

Exhibits

Exhibit No.	Description
99.1	Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2024
99.2	Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2024
99.3	Press Release dated September 30, 2024

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
	By:	/s/ CHOO Chee Kong
	Name:	CHOO<br> Chee Kong
Date:<br> September 30, 2024	Title:	Director<br> and Chairman

Exhibit99.1

CYTOMEDTHERAPEUTICS LIMITED AND SUBSIDIARIES

UNAUDITEDINTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

INDEX

	Page
Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss for the Six months ended June 30, 2023 and 2024	1
Unaudited Interim Condensed Consolidated Statements of Financial Positions as of December 31, 2023 and June 30, 2024	2
Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Six months ended June 30, 2023 and 2024	3
Unaudited Interim Condensed Consolidated Statements of Changes in Equity for the Six months ended June 30, 2023 and 2024	4
Notes to the Unaudited Interim Condensed Consolidated Financial Statements	5

CYTOMEDTHERAPEUTICS LIMITED AND SUBSIDIARIES

UNAUDITEDINTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2024

		Six months ended June 30,
	Notes	2023		2024		2024
		S		S		US
Revenue
Other operating income	5
Other (losses)/gains including fair value changes on financial instruments - net	6		)
Research expenses	7		)		)		)
Depreciation of property, plant and equipment			)		)		)
Amortization of intangible assets			)		)		)
Employee benefits expenses	8		)		)		)
Finance expenses	9		)		)		)
Other expenses	10		)		)		)
Share of result of associate			)
Loss before income tax			)		)		)
Income tax expense
Loss for the period			)		)		)
Other comprehensive loss:
Exchange differences arising from translation of foreign operation			)
Total comprehensive loss for the period			)		)		)
Loss attributable to:
Equity holders of the Company			)		)		)
Non-controlling interests			)		)		)
Total			)		)		)
Total comprehensive loss attributable to:
Equity holders of the Company			)		)		)
Non-controlling interests			)		)		)
Total			)		)		)
Loss per share for loss attributable to equity holders of the Company
-Basic and diluted			)		)		)

All values are in US Dollars.

LOSSPER SHARE

	Six<br> months ended June 30,
	2023		2024
Weighted<br> average number of ordinary shares used in computing basis and diluted loss		9,720,128		11,539,608

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

| 1 |

| --- |

CYTOMEDTHERAPEUTICS LIMITED AND SUBSIDIARIES

UNAUDITEDINTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITIONS

ASOF DECEMBER 31, 2023 AND JUNE 30, 2024

	Notes	December<br> 31, 2023		June 30,<br> 2024		June 30,<br> 2024
		S		S		US
ASSETS
Current assets
Other receivables	11
Cash and bank balances	12
Total current assets
Non-current assets
Property, plant and equipment	13
Intangible assets	14
Investment in associate	15
Other receivables	11
Total non-current assets
Total assets
LIABILITIES AND EQUITY
Current liabilities
Trade and other payables	16
Contract liabilities
Borrowings	17
Warrant liabilities	19
Total current liabilities
Non-current liability
Borrowings	17
Total non-current liability
Total liabilities
Capital and reserves
Share capital	18
Warrant reserve	19
Translation reserve			)		)		)
Accumulated losses			)		)		)
Attributable to equity holders of the Company
Non-controlling interests			)		)		)
Total equity
Total liabilities and equity

All values are in US Dollars.

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

| 2 |

| --- |

CYTOMEDTHERAPEUTICS LIMITED AND SUBSIDIARIES

UNAUDITEDINTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FORTHE SIX MONTHS ENDED JUNE 30, 2023 AND 2024

		Six months ended June 30,
	Notes	2023		2024		2024
		S		S		US
Operating activities
Loss before income tax			)		)		)
Adjustments for:
Amortization of intangible assets
Depreciation of property, plant and equipment
Fair value changes on convertible loans
Fair value changes on warrant liabilities					)		)
Share of result of associate					)		)
Interest expense	9
Interest income	5		)		)		)
Unrealized currency translation differences					)		)
Operating cash flows before movement in working capital			)		)		)
Other receivables			)
Trade and other payables			)		)		)
Cash used in operations			)		)		)
Interest received
Net cash used in operating activities			)		)		)
Investing activities
Purchase of property, plant and equipment	13		)		)		)
Fixed deposits with maturities over 3 months			)		)		)
Deposit paid for acquisition of assets	11				)		)
Loan to a third party					)		)
Net cash used in investing activities			)		)		)
Financing activities
Proceeds from issuance of ordinary shares	18
Principal payment of third party loan			)
Principal payment of bank borrowings			)		)		)
Principal payment of finance lease liabilities			)		)		)
Interest paid	9		)		)		)
Net cash generated from/(used in) financing activities					)		)
Net increase/(decrease) in cash and cash equivalents					)		)
Cash and cash equivalents at beginning of financial period
Effects of currency translation on cash and cash equivalents			)
Cash and cash equivalents at end of financial period	12

All values are in US Dollars.

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

| 3 |

| --- |

CYTOMEDTHERAPEUTICS LIMITED AND SUBSIDIARIES

UNAUDITEDINTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

FORSIX MONTHS ENDED JUNE 30, 2023 AND 2024

	Attributable to equity holders of the Company
									Non-
	Share	Warrant	Translation		Accumulated				controlling		Total
	capital	reserve	reserve		losses		Total		interests		equity
	S	S	S		S		S		S		S
Balance as at 1 January 2023				)		)				)
Total comprehensive loss for the period				)		)		)		)		)
Issuance of new shares
Balance as at 30 June 2023				)		)				)

All values are in US Dollars.


									Non-
	Warrant		Translation		Accumulated				controlling		Total
	reserve		reserve		losses		Total		interests		equity
	S		S		S		S		S		S
Balance as at 1 January 2024				)		)				)
Total comprehensive loss for the period						)		)		)		)
Capitalization of warrant reserve		)
Balance as at 30 June 2024				)		)				)
Balance as at 30 June 2024 (US)		****		****		****		****		****		****

All values are in US Dollars.

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements

| 4 |

| --- |

CYTOMEDTHERAPEUTICS LIMITED AND SUBSIDIARIES

Notesto the Unaudited Interim Condensed Consolidated Financial Statements

Note1 General Information

These unaudited interim condensed consolidated financial statements are the unaudited interim financial statements of CytoMed Therapeutics Limited (the “Company”) and its subsidiaries (the “Group”), for the six months ended June 30, 2024 (the “Financial Statements”).

The Company was incorporated in the Republic of Singapore on March 9, 2018. The Company is a public limited company incorporated and domiciled in Singapore with registered office situated at 1 Commonwealth Lane, #08-22, Singapore 149544. The Company is headquartered in Singapore and conducts its operations domestically and in Malaysia. The Company is listed on the Nasdaq Stock Exchange under the ticker symbol “GDTC” on April 14, 2023.

The principal activities of the Group are to carry on the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy. The Group conducts its primary operations through its directly held wholly owned subsidiary that is incorporated and domiciled in Malaysia, namely CytoMed Therapeutics (Malaysia) Sdn. Bhd., which is principally engaged in manufacturing innate immune cell-based immunotherapy and pluripotent stem cell-based therapy and consultancy services and undertaking the research and development of immune cell and stem cell-based therapy for advancing cellular immunotherapy to treat cancer.

The principal activities of the subsidiaries of the Company are as follows:

Name of entity	Principal activities	Country of<br><br> <br>business /<br><br> <br>incorporation	Group’s effective equity<br><br> <br>interest held
			December 31,		June 30,
			2023		2024
			%		%
CytoMed Therapeutics (Malaysia) Sdn Bhd	Research, development and manufacturing of stem cells and innate immune cell-based immune-therapeutics, research and development of induced pluripotent stem cell-based immune-therapeutics	Malaysia		100		100
Advance Cancer Centre Pte Ltd	Investment, research and development of medical technologies	Singapore		100		100
Puricell Lab Pte Ltd	Research and development of induced pluripotent stem cell-based biologics and medical technologies	Singapore		95		95
LongevityBank Pte Ltd (Formerly known as IPSCBank Pte Ltd)	Stem cell and immune cell banking	Singapore		100		100
Held by LongevityBank Pte Ltd (Formerly known as IPSCBank Pte Ltd)
IPSC Depository Sdn Bhd	Collecting, harvesting, processing, cryopreserving and banking of cells including cord blood stem cells in general; and to carry out research and development on cell-based therapy	Malaysia		100		100

IPSCDepository Sdn Bhd’s principal activities were amended and updated after acquisition of the private blood bank licence.

| 5 |

| --- |

Note2 Summary of significant accounting policies

2.1	Basis<br> of preparation

The unaudited condensed interim consolidated financial statements for the six-month ended June 30, 2024 have been prepared in accordance with IAS 34 Interim Financial Reporting.

The unaudited interim consolidated financial statements do not include all the information and footnotes required by the International Financial Reporting Standards (“IFRS”) for complete financial statements. Certain information and note disclosures normally included in the annual financial statements prepared in accordance with the IFRS have been condensed or omitted consistent with Article 10 of Regulation S-X. In the opinion of the Company’s management, the unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, in normal recurring nature, as necessary for the fair statements of the Company’s financial positions as of June 30, 2024, and results of operations and cash flows for the six-month period ended June 30, 2024. The unaudited interim condensed consolidated statements of financial positions as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by the IFRS. Interim results of operations are not necessarily indicative of the results expected for the full fiscal year or for any future period. These financial statements should be read in conjunction with the audited consolidated financial statements as of and for the years ended December 31, 2023, 2022 and 2021, and related notes included in the Company’s audited consolidated financial statements.

2.2	Adoption<br> of new and amended standards and interpretations

The accounting policies adopted are consistent with those of the previous financial year except that in the current financial year, the Group has adopted all the new and amended standards which are relevant to the Group and are effective for annual financial period beginning on January 1, 2024. The adoption of these standards did not have any material effect on the unaudited interim condensed consolidated financial statements of the Group.

2.3	Convenience<br> translation

All translations from Singapore dollars to U.S. dollars and from U.S. dollars to Singapore dollars in this Report are made at a rate of S$1.3552 to U.S.$1.00, the exchange rate in effect as of June 30, 2024 as set forth in the H.10 statistical release of the U.S. Board of Governors of the Federal Reserve System.

2.4	Going<br> concern assumptions

Prudent liquidity risk management implies sufficient cash to finance the Group’s and the Company’s operations and development activities. The Group manages the liquidity risk by maintaining a level of cash and cash equivalents deemed adequate to finance the Group’s business operations and development activities. The Group’s objective is to maintain a balance between continuing of funding and flexibility through the use of borrowings.

On April 18, 2023, the Company completed its initial public offering. In this offering, the Company issued 2,412,369 ordinary shares at a price of U.S.$4.00 per share for aggregate gross proceeds of S$12,938,017. As of June 30, 2024, the Group has negative cash flow from operating activities of S$1,155,878. The Group’s working capital was positive S$7,349,681 as of June 30, 2024. At the same time, the Group had S$6,471,648 in cash and bank balances, which is unrestricted as to withdrawal and use as of June 30, 2024. In view of these circumstances, the management of the Group has given consideration to the future liquidity and performance of the Group and its available sources of finance in assessing whether the Group will have sufficient financial resources to continue as a going concern, at least, for the next twelve months from the date of this report.

Note3 Significant accounting judgements and estimates

The preparation of the unaudited condensed interim consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in the future periods.

The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as of and for the year ended December 31, 2023.

Note4 Segment information

Segment information by operating segment is not presented as the Group’s operating segment relates solely on the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy.

| 6 |

| --- |

Note5 Other operating income

	June 30, 2023		June 30, 2024
	S		S
Other operating income
Grant (reversal)/income		)
Research income
Interest income
Others

All values are in US Dollars.

Note6 Other losses/(gains) including fair value changes on financial instruments - net

	June 30, 2023		June 30, 2024
	S		S
Other losses/(gains) including fair value changes on financial instruments - net
Fair value loss on convertible loans
Fair value gain on warrant liabilities (Note 19)				)
Net currency exchange gain		)		)
				)

All values are in US Dollars.

The Group measures the warrant liabilities at fair value using Black-Scholes option pricing model.

Note7 Research expenses

	June 30, 2023	June 30, 2024
	S	S
Research expenses
Employee benefits expenses (Note 8)
Depreciation of property, plant and equipment
Amortization of intangible assets
Laboratory consumables
Facility-related expenses
Pre-clinical expenses
Professional expenses
Royalty & licence expenses
Utilities
Other services and fees

All values are in US Dollars.

Research expenses include research personnel costs, depreciation of research equipment and laboratory consumables for research activities.

| 7 |

| --- |

Note8 Employee benefits expenses

	June 30, 2023		June 30, 2024
	S		S
Employee benefits expenses
Wages and salaries
Directors’ fees
Employer’s contribution to defined contribution plans
Other short-term benefits

Less: Classified as “Research expenses”		)		)

All values are in US Dollars.

Employee benefits are recognized as an expense, unless the cost qualifies to be capitalized as a development expenditure.

Note9 Finance expenses

	June 30, 2023	June 30, 2024
	S	S
Finance expenses
Bank borrowings
Convertible loans
Other loan
Lease liabilities

All values are in US Dollars.

Finance expenses arising from bank borrowings, loans and leases liabilities are presented as financing activities in the Unaudited Interim Condensed Consolidated Statements of Cash Flows.

Note10 Other expenses

	June 30, 2023	June 30, 2024
	S	S
Other expenses
Advertising
Annual listing fee
Company insurance
Cleaning fee
Entertainment
Delivery/freight charges
Information technology expenses
Investor relationship expenses
Professional fees
Property tax
Printing and stationery
Legal fees
Lease of low-value assets
Repairs and maintenance
Service fee
Subscription fee
Transportation and travelling
Tools and supplies
Water and electricity
IPO professional expenses
Others

All values are in US Dollars.

| 8 |

| --- |

Note11 Other receivables

	December 31, 2023	June 30, 2024
	S	S
Current assets
Deposits
Prepayments
Prepaid consumables
Interest receivables
Other receivables - third parties

Non-current assets
Amount due from third party

All values are in US Dollars.

As of June 30, 2024, included in the deposits is a deposit of S$330,970 (equivalent to RM1.15 million) (December 31, 2023: Nil) paid to a third party for the acquisition of assets and licence relating to the cord blood banking business.

As of June 30, 2024, the amount due from third party of S$500,000 is loan to a third party with a maturity tenure of 3 years and collectible by the end of 3-year tenure (December 31, 2023: Nil) which bears interest rate of 5.0% (December 31, 2023: Nil) per annum to carry out an investigator initiated trial in People’s Republic of China. The Group commits a total of loan up to S$1,000,000 in accordance with the Heads of Agreement entered into between the Group and the said third party on December 1, 2023 and the remaining loan commitment amounting to S$500,000 is disclosed in the Note 20 to these unaudited interim condensed consolidated financial statements.

Note12 Cash and bank balances

	December 31, 2023		June 30, 2024
	S		S
Cash and bank balances
Cash at banks and on hand
Short-term fixed deposits

Less: Fixed deposits with maturities over 3 months		)		)
Cash and cash equivalents on Unaudited Interim Condensed Consolidated Statements of Cash Flows

All values are in US Dollars.

As of June 30, 2024, fixed deposits are placed for varying periods of between 1 month and 12 months (December 31, 2023: 1 month and 12 months), carried interests between 5.25% and 5.37% (December 31, 2023: 2.20% and 5.55%) per annum.

| 9 |

| --- |

Note13 Property, plant and equipment

The Group acquired property, plant and equipment, excluding right-of-use assets, amounting to approximately S$579,143 as of June 30, 2024 (December 31, 2023: S$58,295) and there was no disposal of assets as of June 30, 2024 and December 31, 2023. The acquisition is mainly due to the purchase of a property in Johor, Malaysia for business expansion. As of June 30, 2024, bank borrowing is secured by a freehold land and a building of the Group with the carrying amount of S$891,606 (December 31, 2023: S$894,487).

Property, plant and equipment is tested for impairment when there is any objective evidence or indication that these assets may be impaired. Impairment exists when the carrying value of an asset or cash-generating-units (“CGU”) exceeds its recoverable amount. The recoverable amount of property, plant and equipment has been determined based on higher of the fair value less costs to sell or value-in use (“VIU”) calculations. If the carrying amount exceed the recoverable amount, an impairment is recognized to profit or loss for the differences.

Property, plant and equipment mainly consist of freehold land, building, and laboratory equipment. Management has assessed that there were no objective evidence or indication that the carrying amount of the Group’s property, plant and equipment may not be recoverable as at the end of reporting date. Accordingly, impairment assessment is not required.

Note14 Intangible assets

	December 31, 2023	June 30, 2024
	S	S
Intangible assets
Goodwill
Intellectual properties licenses
Computer software licenses

All values are in US Dollars.

There is no acquisition or disposal of intangible assets as of June 30, 2024 and December 31, 2023. The movement is mainly due to amortization expense.

| 10 |

| --- |

Note15 Investment in associate

The increase is due to share of gains of the associate, Landmark Medical Centre Sdn Bhd, a full licensed private hospital as of June 30,2024.

Investment in associate is tested for impairment when there is any objective evidence or indication that these assets may be impaired. Impairment exists when the carrying value of an asset or CGU exceeds its recoverable amount. The recoverable amount of investment in associate has been determined based on higher of the fair value less costs to sell or VIU calculations. If the carrying amount exceed the recoverable amount, an impairment is recognized to profit or loss for the differences.

Management has assessed the recoverable amount of the investment in associate calculation based on its VIU, using discounted cash flow forecasts covering a five-year period in which the management made judgements over certain key inputs in relation to cash flows, revenue growth rates and discount rate. It was concluded that the fair value less costs of disposal did not exceed the VIU. As a result of this analysis, no further impairment loss is required to be recognized as at the end of reporting date.

Note16 Trade and other payables

	December 31, 2023	June 30, 2024
	S	S
Trade and other payables
Trade payables
Other payables - third parties
Accrued operating expenses
Deferred income

All values are in US Dollars.

Note17 Borrowings

	December 31, 2023	June 30, 2024
	S	S
Borrowings
Current
Bank borrowings
Lease liabilities

Non-current
Bank borrowings
Lease liabilities

Total borrowings

All values are in US Dollars.

| 11 |

| --- |

Note18 Share capital

	Number of
	Ordinary shares		Amount
			S
June 30, 2024
Beginning of the financial period		11,529,328
Capitalization of warrant reserve		10,672
End of the financial period		11,540,000
December 31, 2023
Beginning of the financial year		8,444,460
Conversion from convertible loans		672,499
Issuance of ordinary shares		2,412,369
End of the financial year		11,529,328

All values are in US Dollars.

On January 17, 2023, the Company implemented a 1-for-380.83 reverse split of our ordinary shares pursuant to which shareholders received one (1) ordinary share for every 380.83 ordinary shares held as of such date. The reverse split proportionally reduced the number of authorized share capital. The paid-up ordinary shares have no par value and carry one vote per share and carry a right to dividends as and when declared by the Company.

On January 26, 2023, the Company converted the convertible loan of S$250,000 into 82,990 ordinary shares. Upon conversion, the 82,990 ordinary shares carried at the conversion value of S$499,996. These newly issued shares rank pari passu in all respects with the previously issued shares.

On April 18, 2023, the Company completed the IPO on the Nasdaq Capital Market, whereby issued and sold 2,412,369 ordinary shares at a price to the public of U.S.$4.00 per share for aggregate gross proceeds of S$12,938,017. The offering expenses of S$1,630,993 which were attributable to the offer of new shares are deducted from equity.

On April 21, 2023, the Company converted the convertible loan of S$1,500,000 into 589,509 ordinary shares. Upon conversion, the 589,509 ordinary shares carried at the conversion value of S$2,999,995. These newly issued shares rank pari passu in all respects with the previously issued shares.

On January 3, 2024, the Company converted 36,185 warrants into 7,860 ordinary shares on a cashless basis. Upon conversion, the 7,860 ordinary shares carried at the value of S$54,154. These newly issued shares rank pari passu in all respects with the previously issued shares.

On January 17, 2024, the Company converted 12,062 warrants into 2,812 ordinary shares on a cashless basis. Upon conversion, the 2,812 ordinary shares carried at the value of S$19,776. These newly issued shares rank pari passu in all respects with the previously issued shares.

| 12 |

| --- |

Note19 Warrant liabilities

	December 31, 2023	June 30, 2024
	S	S
Warrant liabilities
At beginning of financial year/period
Change in the financial year/period			)
Currency realignment
At end of financial year/period

All values are in US Dollars.

The outstanding Representative’s Warrants are recognized as a warrant liability as of 31 December 2023 and are measured at fair value at their inception date and subsequently remeasured using Black-Scholes option pricing model at each reporting period with changes being recorded in the statement of profit or loss.

Warrant reserve amounting to S$73,930 represents 48,247 warrants exercised by various third parties in financial year ended December 31, 2023. It was capitalized in the six months financial period ended June 30, 2024 upon the completion of share registration.

Note20 Capital and other commitments

The following table summarizes the Group’s capital and other commitments as of June 30, 2024:

	Payment Due by Period
	Total	Less than<br> 1 year	Between<br> 1 and 2<br> years	Between<br> 2 and 5<br> years	Over 5<br> years
	S	S	S	S	S
Commitment:
Minimum royalty commitments ^(1)^
Capital commitments ^(2)^
Loan commitments ^(3)^

All values are in US Dollars.

(1)	Relating<br> to the minimum royalty payments under the licensing agreements.
(2)	Relating<br> to the acquisition of assets and licence relating to the cord blood banking<br>business.
(3)	Relating<br> to a loan to third party at 5.0% interest per annum.

Note21 Events occurring after balance sheet date

The Company has assessed all events which occurred from June 30, 2024, up through September 30, 2024, which is the date that these unaudited interim condensed consolidated financial statements are available to be issued. Other than the events disclosed below, there are no material subsequent events that would require disclosure in the unaudited interim condensed consolidated financial statements.

On May 6, 2024, the Company’s indirect subsidiary, IPSC Depository Sdn Bhd (“IPSC”), entered into a master agreement with a third party (the “Vendor”) for the acquisition of a cord blood banking licence, equipment and other assets (“Movable Assets”) and two freehold properties located in Kuala Lumpur, Malaysia (“Immovable Assets”) for a total cash consideration of RM 2.3 million (equivalent to S$661,940).

A total deposit of RM1.15 million (equivalent to S$330,970) was paid to the Vendor as of June 30, 2024 which was classified as “other receivables” and disclosed in Note 11.

On July 17, 2024, IPSC entered into two sales and purchase agreements as part of the master agreement for the acquisition of the Immovable Assets for a total purchase price of RM 2 million (equivalent to S$575,600). The Company expects the acquisition of the Immovable Assets to be completed by end of the year.

On August 1, 2024, IPSC completed the takeover of the Movable Assets.

On September 23, 2024, the Company entered into a clinical study agreement with National University Hospital (“NUH”), Singapore for recruitment of patients under the first-in-human ANGELICA Trial to evaluate the safety of CTM-N2D in human subjects. The earlier clinical study agreement signed with NUH on March 10, 2023 was for the recruitment of healthy blood donors.

| 13 |

| --- |

Exhibit99.2

MANAGEMENT’SDISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2024

Thefollowing discussion and analysis of our financial condition and results of operations should be read in conjunction with the unauditedinterim condensed consolidated financial statements and the notes thereto, included as Exhibit 99.1 to this Report on Form 6-K. We alsorecommend that you read our discussion and analysis of financial condition and results of operations together with our audited financialstatements and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended December 31, 2023 (the “AnnualReport”), filed with the Securities and Exchange Commission (“SEC”) on April 22, 2024.

Alltranslations from Singapore dollars to U.S. dollars and from U.S. dollars to Singapore dollars in this Report are made at a rate of S$1.3552to U.S.$1.00, the exchange rate in effect as of June 30, 2024 as set forth in the H.10 statistical release of the U.S. Board of Governorsof the Federal Reserve System.

EmergingGrowth Company Status

We are an “emerging growth company” under the JOBS Act. The JOBS Act, permits that an “emerging growth company” may take advantage of the extended transition period for complying with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to avail ourselves of delayed adoption of certain accounting standards. Accordingly, our financial statements may not be comparable to the financial statements of public companies that comply with such new or revised accounting standards. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley Act.

We will remain an emerging growth company until the earliest of (i) the last day of the financial year in which we have more than U.S.$1.235 billion in annual revenue, (ii) the date we qualify as a “large accelerated filer” as defined in Rule 12b-2 under Exchange Act, which would occur if the market value of our ordinary shares held by non-affiliates exceeded U.S.$700 million, (iii) the issuance, in any three-year period, by us of more than U.S.$1 billion in non-convertible debt securities, and (iv) the last day of the financial year ending after the fifth anniversary of our initial public offering.

Overview

We are a pre-clinical biopharmaceutical company focused on the R&D of allogeneic, “off-the-shelf” donor cell-based immunotherapies for treatment of human cancers. The development of our novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. All of our product candidates are designed to be allogeneic, meaning they are produced using cells from a different person than the patient treated, as well as on an “off-the-shelf” basis, unlike existing autologous cell therapies. Built on our proprietary platform technologies, we are developing four product candidates: CTM-N2D, iPSC-gdNKT, CTM-GDT and CTM-MSC.

The investigator-initiated Phase 1 trial of our lead product candidate, CTM-N2D with National University Hospital Singapore (the “ANGELICA Trial”), has started in July 2023 with the donor recruitment to obtain healthy donor peripheral blood mononuclear cells which would serve as starting material for manufacturing of CTM-N2D for patients in the trial. We anticipate recruiting our first patient in the last quarter of 2024.

Our second product candidate iPSC-gdNKT utilizes induced pluripotent stem cells as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a natural killer cell. The hybrid cells express receptors of both cells which potentially allow the gdNKT cells to recognize and treat a broad range of cancers. This product has been undergoing pre-clinical process development since the fourth quarter of 2022, and is targeting to commence pre-clinical studies next year in 2025.

Our third product candidate, CTM-GDT consists of expanded unmodified allogeneic gamma delta T cells and exploits the potential of these cells to recognize and treat a broad range of cancers. We are working with The University of Texas M.D. Anderson Cancer Center on using CTM-GDT against lymphoma and breast cancer in pre-clinical studies. Through a US agent, we have submitted a drug master file to US FDA and intend to pursue an investigational new drug application in the near future.

We have not generated any revenue from commercial sale to-date and have incurred losses since our incorporation in 2018. We expect that our expenses and capital requirements will continue to increase for the foreseeable future as we continue developing and seeking regulatory approvals for our product candidates, building our intellectual property portfolio, developing our supply chain, conducting business planning, maintaining our own centralized cGMP facility, hiring and training staff, and ultimately establishing a sales organization.

| 1 |

| --- |

FinancialOperations Overview

Revenue

Since our incorporation, we have not generated any revenue from products approved by regulators and do not expect to generate any such revenue from the commercial sale in the foreseeable future. As of the date of this Report, we have no therapeutic products approved for sale commercially. If our development efforts for one or more of our product candidates are successful and result in regulatory approval, domestically or internationally, or if we enter into collaboration with third parties, we may generate revenue from a combination of product sales or payments from collaboration in the future. We are seeing increasing interest in our products from international parties in 2024.

OtherOperating Income

Other operating income primarily consists of research income, government grants received and support in relation to the technology innovation and interest income.

Other operating income increased by S$188,079 from S$233,684 for the six months ended June 30, 2023, to S$421,763 for the six months ended June 30, 2024. This growth was primarily due to higher interest income from the placement of IPO proceeds in fixed deposits amidst a slight decrease in research income.

Other(Losses)/Gains including fair value changes on financial instruments - net

The Group reported other losses of S$17,608 for the six months ended June 30, 2023, compared to other gains of S$360,871 for the comparable period in 2024. The increase of S$378,479 was mainly driven by an increase in net currency exchange gains and fair value gain on warrant liabilities.

ResearchExpenses

Research expenses were S$811,319 and S$974,402 for the six months ended June 30, 2023 and 2024, respectively. The increase of S$163,083 was mainly due an increase of pre-clinical expenses of S$223,878, higher employee benefits of S$46,745, partially offset by a reduction in laboratory consumables of S$65,857, decrease in professional fees and depreciation expenses.

EmployeeBenefits Expenses

Employee benefits expenses increased by S$151,653 from S$147,514 for the six months ended June 30, 2023 to S$299,167 for the six months ended June 30, 2024. The increase is mainly due to increase in headcount and employee compensation.

FinanceExpenses

Finance expenses decreased by S$30,953, from S$40,758 for the six months ended June 30, 2023, to S$9,805 for the six months ended June 30, 2024. This is primarily attributed to the absence of convertible loan interest in 2024, as the convertible loans were converted into ordinary shares during the six months financial period ended June 30, 2023.

OtherExpenses

Other expenses were S$1,302,531 and S$557,593 for the six months ended June 30, 2023 and 2024, respectively. The decrease of S$744,938 was primarily due to the absence of S$758,563 in IPO professional expenses, lower investor relationship expenses, partially offset by an increase in service fees as detailed in Note 10 of the unaudited interim condensed consolidated financial statements.

| 2 |

| --- |

Shareof results of associate

Share of results of associate consisted of the share of post-acquisition results of an associate incorporated in Malaysia, Landmark Medical Centre Sdn Bhd, a full licensed private hospital during the financial year and its impairment loss.

Share of loss of associate was recorded at S$19,757 for the six months ended June 30, 2023. Share of results of S$15,940 represented the share of profit from the associate for the comparable period in 2024.

Lossfor the period

As a result of the foregoing, we had net loss of S$1,088,543 (equivalent to US$803,235) for the six months ended June 30, 2024 compared to a net loss of S$2,158,247 for the six months ended June 30, 2023. This represented a loss mitigation of 49.6%. There is significant cost advantage operating in Southeast Asia. If the costs associated with being a public listed company of S$153,920 are excluded, the loss for the six months ended June 30, 2024 will be reduced to S$934,623 (equivalent to US$689,657). We expect to continue to incur losses for the foreseeable future in connection with our ongoing activities. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and commercialization of one or more of our product candidates.

Liquidityand Capital Resources

As of December 31, 2023 and June 30, 2024, we had cash and bank balances of S$9.00 million and S$6.47 million, respectively. Our liquidity and working capital requirements primarily related to our operating expenses. Historically, we have met our working capital and other liquidity requirements primarily through private equity financing and issuance of convertible loans. Going forward, we expect to fund our working capital and other liquidity requirements from various sources, including but not limited to the net proceeds from our IPO and other equity and debt financings as and when appropriate.

Based on our current operating plans, we believe that the net proceeds from our offering, together with our current resources, will be sufficient to meet our current and anticipated working capital requirements and capital expenditures for at least the next 1.5 years from the date of this Report. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.

CashFlows

OperatingActivities

During the six months ended June 30, 2023, net cash used in operating activities was S$2.03 million. This was primarily attributable to the loss for the period of S$2.16 million, adjusted for non-cash charges that primarily included depreciation and amortization of S$203,089 and fair value loss on convertible loans of S$98,754, and S$40,758 in interest expenses, S$32,668 in interest income, S$19,757 in share of results of associate and a S$264,416 net change in working capital.

During the six months ended June 30, 2024, net cash used in operating activities was S$1.16 million. This was primarily attributable to a loss for the year of S$1.09 million, adjusted for non-cash items including S$166,870 in depreciation and amortization and S$150,238 in fair value gain on warrant liabilities, S$9,805 in interest expenses, S$190,540 in interest income, S$15,940 in share of results of associate, and S$171,296 net change in working capital.

| 3 |

| --- |

InvestingActivities

Net cash used in investing activities during the six months ended June 30, 2023 was S$5,459,928, mainly due to the placement of S$5,442,800 fixed deposits with maturities over 3 months.

Net cash used in investing activities during the six months ended June 30, 2024 was S$1,887,790, mainly due to S$579,143 used in purchase of property in Johor, Malaysia for business expansion, the placement of S$477,677 fixed deposits with maturities over 3 months, S$330,970 deposit paid to the acquisition of assets and S$500,000 loan to a third party.

FinancingActivities

During the six months ended June 30, 2023, net cash generated from financing activities was S$10.92 million mainly due to the proceeds from IPO of S$11.31 million, partially offsetting by the repayment of a third-party loan of S$300,000.

During the six months ended June 30, 2024, net cash used in financing activities was S$29,542 mainly due to repayment of bank borrowings of S$15,978 and interest payment of S$9,805.

Off-BalanceSheet Arrangements

We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.

Quantitativeand Qualitative Disclosures about Market Risks

We are exposed to market risks in the ordinary course of our business. These risks primarily include currency risk and interest rate risk.

Currencyrisk

We operate in Southeast Asia with dominant operations in Singapore and Malaysia. We regularly transact in currencies other than our respective functional currencies (“foreign currencies”). Currency risk arises when transactions are denominated in foreign currencies other than functional currency. In addition, we are exposed to currency translation risk on the net assets in foreign operations.

Interestrate risk

As of December 31, 2023 and June 30, 2024, we had cash and bank balances of S$9.00 million and S$6.47 million. Our exposure to interest rate sensitivity is impacted by changes in the underlying US bank interest rates. We have not entered into investments for trading or speculative purposes.

RecentDevelopments

A total deposit of RM1.15 million (equivalent to S$330,970) was paid to the Vendor as of June 30, 2024 which was classified as “other receivables” and disclosed in Note 11 of the unaudited interim condensed consolidated financial statements.

On August 1, 2024, IPSC completed the takeover of the Movable Assets.

| 4 |

| --- |

Exhibit99.3

CytoMedTherapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

Conferencecall via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT)

https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT

Singapore– (September 30, 2024) – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived, cell-based allogeneic immunotherapies for the treatment of a broad range of cancers including blood and solid tumors, today announced six months ended June 30, 2024 financial results and provided clinical and corporate updates.

“We are committed to advancing our “off-the-shelf” allogeneic cellular immunotherapies for a broad spectrum of cancer,” said Peter Choo, Chairman of CytoMed. “Taking advantage of our Southeast Asia’s low cost infrastructure and collaboration with our partners, we have made extraordinary progress thus far and look towards internationalization of our operations and provide affordable cancer care to no-option sufferers.”

“Various international parties have approached us with interest in our proprietary gamma delta T cells, validating our off-the-shelf cell therapy technology and this can further accelerate the reach of our cells internationally,” said Dr Tan Wee Kiat PhD, the Co-CEO and COO of CytoMed.

ClinicalUpdates

In January 2023, the Company received formal approval from the Health Sciences Authority (“HSA”) in Singapore to conduct a first-in-human Phase I clinical trial (“ANGELICA Trial”) and has begun to recruit blood donors in July 2023. The ANGELICA Trial, in partnership with the National University Hospital (“NUH”), Singapore, will use healthy donor blood to manufacture allogeneic CAR-γδ T cells (“CTM-N2D”). The cells will be processed in CytoMed’s own current Good Manufacturing Practice (“cGMP”) facility in Malaysia.

The ANGELICA Trial comprises two parts. Part 1 (donor protocol) is ongoing with the recruitment of healthy blood donors at NUH. With the continued collaboration between CytoMed and NUH, the second part of the trial (recipient protocol) may now proceed with the recruitment of patients who have advanced cancers that are resistant to standard therapy regimens.

As of September 2024, the Company are translating two proprietary, exclusively licensed technologies, namely donor blood cell-based CAR-γδ T cell technology and induced pluripotent stem cell-based γδ NKT cell technology. The former has been granted patents in the US, China and Malaysia, the latter in China, Japan and Malaysia.

FinancialResults for the Six months ended June 30, 2024

Net Loss: For the six months ended June 30, 2024, the Company’s unaudited net loss amounted to S$1.09 million (equivalent to US$803,235). If the costs associated with being a public listed company (listed on NASDAQ in April 2023) of S$153,920 are excluded, the loss for the six months ended June 30, 2024 will be reduced to S$934,623 (equivalent to US$689,657).

Cash and Bank Balances: As of June 30, 2024, the Company had cash and bank balances of S$6.47 million (equivalent to US$4.78 million).

Research Expenses: The Company’s research and development expenses were S$974,402 (equivalent to US$719,010) and S$811,319 for the six months ended June 30, 2024 and 2023, respectively. The increase of S$163,083 was mainly due an increase of pre-clinical expenses and higher employee benefits. This was partially offset by a reduction in laboratory consumables, decrease in professional fees and depreciation expenses.

G&A Expenses: The Company’s general and administrative expenses were S$902,910 (equivalent to US$666,256) and S$1.50 million for the six months ended June 30, 2024 and 2023, respectively. The decrease was primarily driven by non-recurring IPO expenses and the costs associated with being a public listed company in year 2023.

ConferenceCall Information

Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT). The investment community may participate in the conference call by tuning into the following Zoom:

https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT

The management team will be available in New York City from October 28, 2024 to November 1, 2024 for meetings with shareholders and potential investors. Please contact us at enquiry@cytomed.sg if you wish to schedule a meeting.

AboutCytoMed Therapeutics Limited (CytoMed)

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. It is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating hematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.

ForwardLook Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&D programs; the Company’s expectations regarding the impact of the ongoing COVID-19 pandemic on its business, the Company’s industry and the economy; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

Contacts:

CytoMed Therapeutics Limited

Email: enquiry@cytomed.sg

Attention: Evelyn Tan, Chief Corporate Officer